Production (Stage)
BetterLife Pharma Inc.
BETR
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -79.73% | 4.81% | 24.44% | -1.29% | 206.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.18% | -17.75% | 1.69% | 6.69% | 195.26% |
| Operating Income | 80.18% | 17.75% | -1.69% | -6.69% | -195.26% |
| Income Before Tax | 90.35% | -5.08% | 399.11% | -37.31% | -112.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 90.35% | -5.08% | 399.11% | -37.31% | -112.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -104.11% | 104.90% | -322.96% | 3.23% | -82.72% |
| Net Income | 89.63% | 46.34% | 406.18% | -37.57% | -422.66% |
| EBIT | 80.18% | 17.75% | -1.69% | -6.69% | -195.26% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 91.13% | 52.38% | 361.54% | -24.29% | -359.26% |
| Normalized Basic EPS | 86.96% | 61.11% | 112.50% | -22.73% | -9,100.00% |
| EPS Diluted | 89.47% | 29.76% | 330.77% | -16.00% | -79.73% |
| Normalized Diluted EPS | 86.96% | 61.11% | 112.50% | -22.73% | -9,100.00% |
| Average Basic Shares Outstanding | 12.26% | 12.73% | 14.73% | 10.31% | 15.89% |
| Average Diluted Shares Outstanding | 12.26% | 12.73% | 30.05% | 10.31% | 15.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |